CJC-1295
A modified growth-hormone-releasing hormone analog with extended half-life that amplifies natural GH pulsatility.
Also known as: DAC:GRF, Modified GRF 1-29, CJC-1295 DAC, CJC-1295 no DAC, Mod GRF
Regulatory Status
Classification date: 2026-02-27
Reclassification to Category 1 announced but not yet formalized
Compounding: Not currently available for compounding
Evidence Summary
Key Studies
How It Works
CJC-1295 is a synthetic analog of GHRH (residues 1-29) with amino acid substitutions that resist DPP-IV enzymatic cleavage. The DAC (Drug Affinity Complex) version binds albumin for a half-life of 6-8 days, providing sustained GH elevation. The no-DAC variant (Mod GRF 1-29) has a shorter half-life of ~30 minutes, preserving more physiologic pulsatile GH release. Both versions act on the GHRH receptor and are frequently combined with ghrelin mimetics like ipamorelin for synergistic effect.
Common Applications
Safety & Considerations
Common side effects include water retention, flushing, and transient numbness/tingling. The DAC version can cause sustained GH elevation that may produce side effects similar to mild GH excess (joint stiffness, carpal tunnel symptoms). The no-DAC version is generally preferred for more physiologic dosing. Not studied in long-term human trials. Currently not legal for compounding in the US.
Related Research
Regulatory classifications can change rapidly. The information shown here was last verified on 2026-02-27. Always confirm current legal status with a licensed provider or the FDA before making treatment decisions.